176 related articles for article (PubMed ID: 18605224)
1. Optimal therapy for rare disorders and genetic diseases: ethical and political challenges.
MacLeod S
Proc West Pharmacol Soc; 2007; 50():21-3. PubMed ID: 18605224
[TBL] [Abstract][Full Text] [Related]
2. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
3. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
4. Managing drugs for rare genetic diseases: trends and insights.
Zitter M
Manag Care; 2005 Feb; 14(2):52-4, 57-60, 63-4; quiz 66-7. PubMed ID: 15782848
[TBL] [Abstract][Full Text] [Related]
5. Developing treatments for inborn errors: incentives available to the clinician.
Haffner ME
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
[TBL] [Abstract][Full Text] [Related]
6. [Hope for patients with rare diseases--"orphan" drugs].
Kuzelová M; Kubácková K; Palágyi M; Smíd M
Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
[TBL] [Abstract][Full Text] [Related]
7. Orphan drugs revisited.
McCabe C; Tsuchiya A; Claxton K; Raftery J
QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
[No Abstract] [Full Text] [Related]
8. Rare diseases, orphan drugs, and orphaned patients.
Scheindlin S
Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
[No Abstract] [Full Text] [Related]
9. [Orphanet and the Dutch Steering Committee Orphan Drugs. A European and Dutch databank of information on rare diseases].
Liem SL
Ned Tijdschr Tandheelkd; 2008 Nov; 115(11):621-3. PubMed ID: 19058507
[TBL] [Abstract][Full Text] [Related]
10. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.
Pinxten W; Denier Y; Dooms M; Cassiman JJ; Dierickx K
J Med Ethics; 2012 Mar; 38(3):148-53. PubMed ID: 21947805
[TBL] [Abstract][Full Text] [Related]
11. [Orphan drugs and orphan diseases].
Campos-Castelló J
Rev Neurol; 2001 Aug 1-15; 33(3):216-20. PubMed ID: 11588712
[TBL] [Abstract][Full Text] [Related]
12. The European rare diseases therapeutic initiative.
Fischer A; Borensztein P; Roussel C
PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring in pediatrics: how do children differ?
Macleod S
Ther Drug Monit; 2010 Jun; 32(3):253-6. PubMed ID: 20463632
[TBL] [Abstract][Full Text] [Related]
14. EU to review rare disease drugs market exclusivity.
Sheridan C
Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
[No Abstract] [Full Text] [Related]
15. Orphan drug legislation: lessons for neglected tropical diseases.
Villa S; Compagni A; Reich MR
Int J Health Plann Manage; 2009; 24(1):27-42. PubMed ID: 18435430
[TBL] [Abstract][Full Text] [Related]
16. [Orphan diseases].
Loizzo A; Tebano MT
Recenti Prog Med; 1993 Nov; 84(11):786-93. PubMed ID: 8290793
[TBL] [Abstract][Full Text] [Related]
17. [Orphan drugs. Drugs for treatment of rare diseases].
Hennemann A
Med Monatsschr Pharm; 2004 Aug; 27(8):256-9. PubMed ID: 15382448
[No Abstract] [Full Text] [Related]
18. [Orphanet: a European database for rare diseases].
Weinreich SS; Mangon R; Sikkens JJ; Teeuw ME; Cornel MC
Ned Tijdschr Geneeskd; 2008 Mar; 152(9):518-9. PubMed ID: 18389888
[TBL] [Abstract][Full Text] [Related]
19. [Rare diseases. Concept, epidemiology and state of the question in Spain].
Posada De la Paz M; Martín-Arribas C; Ramírez A; Villaverde A; Abitua I
An Sist Sanit Navar; 2008; 31 Suppl 2():9-20. PubMed ID: 18953369
[TBL] [Abstract][Full Text] [Related]
20. Drug development for orphan diseases in the context of personalized medicine.
Brewer GJ
Transl Res; 2009 Dec; 154(6):314-22. PubMed ID: 19931198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
